Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | RHOA | P61586 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426356 | 0.83 | PDGFRB (0.71) | BRAFPDGFRBPDGFRAABCG2EGFR | |
| SCHEMBL1401437 | 0.81 | PDGFRB (0.68) | BRAFPDGFRBPDGFRAABCG2RHOA | |
| SCHEMBL11272822 | 0.75 | PDGFRB (0.56) | PDGFRBPDGFRAABCG2RHOASYK | |
| SCHEMBL3428154 | 0.74 | BRAF (1.00) | BRAFPDGFRBTNNI3KTYK2SYK | |
| SCHEMBL4332136 | 0.72 | RAF1 (0.58) | BRAFABCG2 | |
| SCHEMBL7697641 | 0.70 | AURKA (0.54) | PDGFRBPDGFRAABCG2EGFR | |
| SCHEMBL31343895 | 0.70 | PDGFRB (0.68) | PDGFRBPDGFRAABCG2RHOAEGFR | |
| SCHEMBL29514710 | 0.69 | KIF11 (0.54) | ABCG2EGFRTNNI3KHDAC6GRM4 | |
| SCHEMBL21625856 | 0.69 | KIF11 (0.54) | ABCG2EGFRTNNI3KHDAC6GRM4 | |
| SCHEMBL29408383 | 0.68 | GRM4 (0.52) | BRAFABCG2EGFRTNNI3KTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-1680122-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037285-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | CHIRON CORPORATION (US) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | RAF1, BRAF, ARAF | BRAF 2/4885PDGFRB 3928/4885PDGFRA 3747/4885 |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | RAF1, BRAF, ARAF | BRAF 2/4885PDGFRB 3928/4885PDGFRA 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.